Ionis Pharmaceuticals, Inc. (LON:0JDI)
61.11
-2.61 (-4.09%)
At close: Sep 15, 2025
Ionis Pharmaceuticals Revenue
Ionis Pharmaceuticals had revenue of $452.05M USD in the quarter ending June 30, 2025, with 100.69% growth. This brings the company's revenue in the last twelve months to $944.05M, up 16.05% year-over-year. In the year 2024, Ionis Pharmaceuticals had annual revenue of $705.14M, down -10.48%.
Revenue (ttm)
$944.05M
Revenue Growth
+16.05%
P/S Ratio
10.39
Revenue / Employee
$883.12K
Employees
1,069
Market Cap
7.16B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 705.14M | -82.51M | -10.48% |
Dec 31, 2023 | 787.65M | 200.28M | 34.10% |
Dec 31, 2022 | 587.37M | -223.09M | -27.53% |
Dec 31, 2021 | 810.46M | 81.19M | 11.13% |
Dec 31, 2020 | 729.26M | -393.34M | -35.04% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Ionis Pharmaceuticals News
- 4 days ago - Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases - Business Wire
- 4 days ago - Insider Sell: Patrick O'neil Sells 21,000 Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus
- 5 days ago - Ionis: Recent Approvals, Upcoming Catalysts To Spur Strong Upside (Rating Upgrade) - Seeking Alpha
- 6 days ago - Ionis Pharmaceuticals, Inc. (IONS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 6 days ago - Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status - Benzinga
- 6 days ago - Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status - Benzinga
- 6 days ago - Ionis gets FDA breakthrough therapy status for angelman syndrome drug - Seeking Alpha
- 6 days ago - Ionis Pharmaceuticals Inc (IONS) Receives FDA Breakthrough Therapy Designation for ION582 | ... - GuruFocus